Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.6116
-0.0050 (-0.81%)
Oct 29, 2026, 11:58 AM EDT - Market open
Invivyd Employees
Invivyd had 122 employees as of December 31, 2025. The number of employees increased by 22 or 22.00% compared to the previous year. That makes Invivyd the 30,179th largest employer in the world and 3,854th in the United States.
Employees
122
Change (1Y)
22
Growth (1Y)
22.00%
Revenue / Employee
$478,402
Profits / Employee
-$879,779
Market Cap
180.27M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | 22 | 22.00% | 122 | 0 |
| Dec 31, 2024 | 100 | 5 | 5.26% | 99 | 1 |
| Dec 31, 2023 | 95 | 9 | 10.47% | 94 | 1 |
| Dec 31, 2022 | 86 | -17 | -16.50% | 84 | 2 |
| Dec 31, 2021 | 103 | - | - | 101 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Coherus Oncology | 144 |
| Adagene | 128 |
| Compugen | 75 |
| Precision BioSciences | 67 |
| Sionna Therapeutics | 59 |
| PepGen | 57 |
| Whitehawk Therapeutics | 32 |
IVVD News
- 8 days ago - Invivyd presents measles antibody candidate VMS063 data at IDWeek 2026 - TheFly
- 8 days ago - Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 - GlobeNewsWire
- 15 days ago - Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome - GlobeNewsWire
- 24 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Invivyd Phase 3 data supports VYD2311 tolerability, says H.C. Wainwright - TheFly
- 4 weeks ago - Invivyd Transcript: Study result - Transcripts
- 4 weeks ago - Invivyd Press release: Study result - Filings
- 4 weeks ago - Invivyd Slides: Study result - Filings